Seven patents currently held, every record listed here

1 more in force is now held by another company

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Nov 2038. from the record

Free plan: 3 watched companies. Pro: unlimited.

Alerts on its grants, lapses and transfers.

Ending by 2030

Nov 2038

Next term end

Patent families

When these terms end

Each bar runs from grant to computed term end. 2022 to 2043.

US 11,655,246 Aminothiazole Compounds as Inhibitors of CTPS1 Nov 30, 2038

US 12,319,680 Compounds Nov 30, 2038

US 12,503,466 Aminothiazole Compounds as Inhibitors of CTPS1 Nov 30, 2038

US 11,505,547 Compounds Mar 2, 2039

US 12,371,419 Aminopyrimidine/Pyrazine Derivatives as CTPS1 Inhibitors Oct 23, 2039

US 11,987,573 Aminopyrimidine/pyrazine derivatives as CTPS1 inhibitors May 26, 2041

US 12,466,810 N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(methylsulfonamido)pyrimidin-4-yl) tetrahydro-2H-pyran-4-carboxamide derivatives and related compounds as human CTPS1 inhibitors for the treatment of proliferative diseases Aug 16, 2042

US 12,780,793 Sulfonamide Inhibitors as CTPS1 Inhibitors Jun 10, 2043

202620302034203820422043

6 pending applications: term is not computable until grant.Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank

Notable

Compounds US 11,505,547

The most cited patent in this portfolio, cited by 7 later US patents, top 25% of utility patents granted in 2022 in our data. Protection runs to 2039.

Ends Mar 2039 · High confidence Also notable

Aminothiazole Compounds as Inhibitors of CTPS1 US 11,655,246

Cited by 6 later US patents, top 25% of utility patents granted in 2023 in our data. Protection runs to 2038.

Ends Nov 2038 · High confidence Also notable

Aminopyrimidine/Pyrazine Derivatives as CTPS1 Inhibitors US 12,371,419

Granted 2025. Too new for citation comparison; protection runs to 2039.

Ends Oct 2039 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due Nov 23, 2026
The maintenance fee for Aminothiazole Compounds as Inhibitors of CTPS1 (US 11,655,246) comes due Nov 23, 2026. Unpaid by May 24, 2027, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Oct 16Assignment recorded on US 12,371,419: George, Pascal to Step Pharma S.A.S Recorded Oct 16, 2026, executed Apr 21, 2021. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76729, frame 546.
Oct 13Assignment recorded on 1 record: Pascal, George to Step Pharma S.A.S. Recorded Oct 13, 2026, executed Apr 28, 2021. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76671, frame 18.
1 of the patents on this record was granted since Aug 16, 2026

What they patent

Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.

Compounds	2 in force	to Mar 2039
Aminothiazole Compounds as Inhibitors of CTPS1	2 in force	to Nov 2038
Sulfonamide Inhibitors as CTPS1 Inhibitors	1 in force	to Jun 2043
N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(methylsulfonamido)pyrimidin-4-yl) tetrahydro-2H-pyran-4-carboxamide derivatives and related compounds as human CTPS1 inhibitors for the treatment of proliferative diseases	1 in force	to Aug 2042
Aminopyrimidine/Pyrazine Derivatives as CTPS1 Inhibitors	1 in force	to Oct 2039

Patents held now

Soonest term end first.

Showing 1 to 7 of 7

Patent	Title	Status	Expires	Confidence
US 11,655,246	Aminothiazole Compounds as Inhibitors of CTPS1 In force Term ends Nov 30, 2038 · High confidence	In force	Term ends Nov 30, 2038	High confidence
US 12,319,680	Compounds In force Term ends Nov 30, 2038 · High confidence	In force	Term ends Nov 30, 2038	High confidence
US 12,503,466	Aminothiazole Compounds as Inhibitors of CTPS1 In force Term ends Nov 30, 2038 · High confidence	In force	Term ends Nov 30, 2038	High confidence
US 11,505,547	Compounds In force Term ends Mar 2, 2039 · High confidence	In force	Term ends Mar 2, 2039	High confidence
US 12,371,419	Aminopyrimidine/Pyrazine Derivatives as CTPS1 Inhibitors In force Term ends Oct 23, 2039 · High confidence	In force	Term ends Oct 23, 2039	High confidence
US 12,466,810	N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(methylsulfonamido)pyrimidin-4-yl) tetrahydro-2H-pyran-4-carboxamide derivatives and related compounds as human CTPS1 inhibitors for the treatment of proliferative diseases In force Term ends Aug 16, 2042 · High confidence	In force	Term ends Aug 16, 2042	High confidence
US 12,780,793	Sulfonamide Inhibitors as CTPS1 Inhibitors In force Term ends Jun 10, 2043 · High confidence	In force	Term ends Jun 10, 2043	High confidence

Also on record, not counted in the 7: 1 patent in force now held by others · 6 applications pending · 3 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built

Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Step Pharma S.A.S.